A breakthrough in non-invasive cancer treatment that uses your body’s own biology to fight tumors — to fight cancer Tumors.
Targeted Osmotic Lysis (TOL) is a precise treatment that selectively destroys cancer cells. A low-dose cardiac drug opens ion channels specific to tumor cells. A series of gentle electrical pulses then causes those cells to swell and burst — while leaving healthy tissue untouched. No cutting. No chemo. No collateral damage.
Since 1998, Dr. Dennis Paul and Dr. Harry Gould of Louisiana State University have been studying basic cell function, with special focus on how sodium channels respond to injury and disease. Their findings have allowed them to take advantage of a previously known property of malignant cancer cells to devise a novel and promising treatment for many of the deadliest cancers: Targeted Osmotic Lysis (TOL).
Advanced-stage cancer cells express 10 to 50 times more sodium channels in their cell membranes than do normal cells. By stimulating the opening of these channels and enabling the entry of large amounts of sodium while blocking the mechanism to expel the excess ions, Dr. Paul and Dr. Gould have been able to force cancer cells to burst, while leaving healthy cells unharmed. The treatment process uses a generic drug used to treat heart ailments (digoxin) and a new device that produces a pulsed electric field.